LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday it has expanded the terms of its collaboration agreement with Adaptimmune Therapeutics PLC, to accelerate Adaptimmune's lead clinical cancer programme for synovial sarcoma.
The two companies agreed a collaboration and licensing deal in June 2014 for up to five programmes. Glaxo has an option on the lead clinical cancer programme through proof of concept, and on the exercise of this option it will assume full responsibility for the programme.
Under the expanded deal the companies will speed up the development of the therapy into studies in synovial sarcoma, and will also explore its development in myxoid round cell liposarcoma. Additionally, the companies may initiate up to either proof-of-principle studies exploring combinations with other therapies.
In a separate statement, the company also announced that it has made a regulatory submission in the US for its influenza vaccine FluLaval Quadrivalent, seeking to expand its indication for children of six months through to 35 months.
Shares in GlaxoSmithKline were down 0.7% at 1,424.10 pence Tuesday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.